Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Targeting the Phosphoinositide 3-Kinase p110-α Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Republication: Targeting PI3KC2β Impairs Proliferation and Survival in Acute Leukemia, Brain Tumours and Neuroendocrine Tumours.

Anticancer research·2022

Same author

IGF signaling as a therapeutic target in pediatric solid tumors of the central and peripheral nervous system.

Expert review of endocrinology & metabolism·2019

Same author

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Scientific reports·2018

Same author

Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.

PloS one·2017

Same author

2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner.

Oxidative medicine and cellular longevity·2017

Search research articles

Related Experiment Videos

IGF-IR: potential role in antitumor agents.

Ana S Guerreiro¹, Danielle Boller, Kathrin T Doepfner

¹Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Switzerland.

Drug News & Perspectives

|August 31, 2006

Summary

Insulin-like growth factor (IGF) signaling is crucial in cancer. Research focuses on targeting the IGF-I receptor (IGF-IR) with new drugs to inhibit tumor growth, though clinical efficacy timing is uncertain.

Related Experiment Videos

Area of Science:

Oncology
Molecular Biology
Endocrinology

Background:

Insulin-like growth factor (IGF) signaling plays a key role in human cancer development.
Deregulation of the IGF system, including autocrine loops and IGF-I receptor (IGF-IR) overexpression, is common in cancer cells.
Epidemiological studies link elevated IGF levels to major cancers like breast, colon, lung, and prostate.

Purpose of the Study:

To review the evidence implicating the IGF signaling system in human cancer pathology.
To discuss current strategies for targeting the IGF-I receptor (IGF-IR) as an antitumor approach.

Main Methods:

Review of existing literature on IGF signaling in cancer.
Analysis of experimental therapies targeting IGF-IR, including antibodies and kinase inhibitors.
Discussion of preclinical (in vitro and in vivo) antitumor activity data.

Main Results:

The IGF signaling pathway is implicated in the development and progression of various human malignancies.
Preclinical studies demonstrate antitumor activity of IGF-IR targeting agents.
The clinical translation and timeline for demonstrable patient benefit remain to be determined.

Conclusions:

The IGF signaling system is a significant factor in human cancer.
Targeting IGF-IR represents a promising therapeutic strategy for cancer treatment.
Further research is needed to establish the clinical effectiveness and timing of IGF-IR inhibitors in patients.